Chinese (SSE) Clinical Research and Equipment Industry Analysis

Industry Valuation and Performance

Has the Chinese Clinical Research and Equipment Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Mon, 08 Jun 2026	CN¥532.7b	CN¥98.8b	CN¥21.9b	48.3x	24.4x	5.4x
Wed, 06 May 2026	CN¥617.9b	CN¥98.5b	CN¥21.7b	58.6x	28.5x	6.3x
Fri, 03 Apr 2026	CN¥600.1b	CN¥95.0b	CN¥20.6b	58.6x	29.1x	6.3x
Sun, 01 Mar 2026	CN¥592.9b	CN¥94.4b	CN¥18.6b	67.6x	32x	6.3x
Tue, 27 Jan 2026	CN¥606.8b	CN¥94.3b	CN¥18.5b	66.5x	32.7x	6.4x
Thu, 25 Dec 2025	CN¥549.5b	CN¥94.3b	CN¥18.5b	60.8x	29.7x	5.8x
Sat, 22 Nov 2025	CN¥540.9b	CN¥94.3b	CN¥18.5b	63.4x	29.2x	5.7x
Mon, 20 Oct 2025	CN¥570.0b	CN¥92.1b	CN¥17.4b	63.1x	32.7x	6.2x
Wed, 17 Sep 2025	CN¥638.0b	CN¥92.1b	CN¥17.4b	75.5x	36.6x	6.9x
Fri, 15 Aug 2025	CN¥595.5b	CN¥91.6b	CN¥17.9b	61x	33.3x	6.5x
Sun, 13 Jul 2025	CN¥491.2b	CN¥89.8b	CN¥15.4b	51.9x	32x	5.5x
Tue, 10 Jun 2025	CN¥432.8b	CN¥89.8b	CN¥15.4b	49.5x	28.2x	4.8x
Thu, 08 May 2025	CN¥388.9b	CN¥89.3b	CN¥15.1b	40.6x	25.8x	4.4x
Sat, 05 Apr 2025	CN¥425.4b	CN¥88.5b	CN¥14.0b	43.5x	30.3x	4.8x
Mon, 03 Mar 2025	CN¥419.3b	CN¥88.7b	CN¥11.5b	43.5x	36.6x	4.7x
Wed, 29 Jan 2025	CN¥358.6b	CN¥88.1b	CN¥11.2b	37.6x	31.9x	4.1x
Fri, 27 Dec 2024	CN¥372.5b	CN¥87.8b	CN¥11.2b	38.4x	33.3x	4.2x
Sun, 24 Nov 2024	CN¥358.4b	CN¥87.8b	CN¥11.2b	37.6x	32x	4.1x
Tue, 22 Oct 2024	CN¥365.6b	CN¥88.2b	CN¥12.4b	33.2x	29.5x	4.1x
Thu, 19 Sep 2024	CN¥279.4b	CN¥88.2b	CN¥12.4b	27.7x	22.6x	3.2x
Sat, 17 Aug 2024	CN¥286.8b	CN¥87.7b	CN¥12.6b	26.3x	22.8x	3.3x
Mon, 15 Jul 2024	CN¥279.1b	CN¥88.3b	CN¥13.4b	24.6x	20.8x	3.2x
Wed, 12 Jun 2024	CN¥303.0b	CN¥88.3b	CN¥13.4b	27.6x	22.6x	3.4x
Fri, 10 May 2024	CN¥341.9b	CN¥88.3b	CN¥13.3b	31.2x	25.6x	3.9x
Sun, 07 Apr 2024	CN¥336.7b	CN¥90.3b	CN¥15.0b	33.6x	22.4x	3.7x
Tue, 05 Mar 2024	CN¥387.0b	CN¥90.5b	CN¥15.5b	34.1x	25x	4.3x
Thu, 01 Feb 2024	CN¥350.1b	CN¥91.1b	CN¥16.1b	30x	21.8x	3.8x
Sat, 30 Dec 2023	CN¥475.7b	CN¥91.1b	CN¥16.1b	39.4x	29.6x	5.2x
Mon, 27 Nov 2023	CN¥535.9b	CN¥91.1b	CN¥16.1b	39.8x	33.3x	5.9x
Wed, 25 Oct 2023	CN¥508.4b	CN¥92.2b	CN¥18.4b	33.5x	27.6x	5.5x
Fri, 22 Sep 2023	CN¥478.8b	CN¥92.0b	CN¥18.3b	31.7x	26.1x	5.2x
Sun, 20 Aug 2023	CN¥484.0b	CN¥91.6b	CN¥18.6b	33.3x	26.1x	5.3x
Tue, 18 Jul 2023	CN¥459.0b	CN¥91.3b	CN¥18.5b	34.2x	24.8x	5x
Thu, 15 Jun 2023	CN¥481.2b	CN¥91.3b	CN¥18.5b	35.9x	26.1x	5.3x

Current Industry PE

Investors are pessimistic on the Chinese Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.

The industry is trading at a PE ratio of 24.4x which is lower than its 3-year average PE of 28.7x.

The industry is trading close to its 3-year average PS ratio of 5.0x.

Past Earnings Growth

The earnings for companies in the Life Sciences Tools and Services industry have grown 5.8% per year over the last three years.
Revenues for these companies have grown 2.7% per year.
This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does Chinese Clinical Research and Equipment compare with similar industries?


CN Market	-1.40%
Healthcare	-4.61%
Life Sciences	-5.16%
Clinical Research and Equipment	-5.16%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

	Company	Last Price	7D	1Y	Valuation
	688131 Shanghai Haoyuan Chemexpress	CN¥75.00	1.0% +CN¥163.3m	62.5%	PE64.9x

Company

Last Price

Valuation

688131 Shanghai Haoyuan Chemexpress

CN¥75.00

1.0%
+CN¥163.3m

62.5%

PE64.9x

Joinn Laboratories (China) Co., Ltd. Announces Executive Changes

JOINN Laboratories (China) Co. Ltd. held its annual general meeting on June 4, 2026. The resolution on the appointment of Mr. Zhou Fengyuan as a non-executive Director was passed by the Shareholders at the AGM. The term of Mr. Zhou commences from the date of the AGM and terminates upon the expiry of the fifth session of the Board. As required under Rule 13.51(2) of the Listing Rules, the biographical details of Mr. Zhou Fengyuan have been set out in the Circular. To the best knowledge of the Directors and save as disclosed in the Circular, Mr. Zhou (i) has no relationship with any Directors, senior management, substantial Shareholders or controlling Shareholders (as respectively defined in the Listing Rules) of the Company; (ii) does not hold any other position with the Company or its subsidiaries; (iii) did not hold any directorships in any other listed companies the securities of which are listed on any securities markets in Hong Kong or overseas in the last three years; (iv) is not interested in nor is deemed to be interested in any shares or underlying shares of the Company or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and (v) has no other matters relating to his appointment that need to be brought to the attention of the Shareholders or the Stock Exchange or to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules. The Board resolved to appoint Mr. Gu Jingliang, Mr. Zhou Fengyuan, Mr. Zhang Fan and Mr. Yang Fuquan as members of the Strategic Development Committee. The Strategic Development Committee will therefore comprise eight Directors, namely Ms. Feng Yuxia, Ms. Sun Yunxia, Mr. Gu Jingliang, Ms. Luo Xi, Mr. Zhou Fengyuan, Mr. Zhang Fan, Mr. Yang Fuquan and Mr. Ying Fangtian and is chaired by Ms. Feng Yuxia. The term of the aforesaid members of the Strategic Development Committee commences from the date of the AGM and terminates upon the expiry of the fifth session of the Board.

Chinese (SSE) Clinical Research and Equipment Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

Joinn Laboratories (China) Co., Ltd. Announces Executive Changes

603259: Conviction List Inclusion And Buybacks Are Expected To Support Future Earnings

New minor risk - Share price stability

Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 12, 2026

Beijing Hotgen Biotech Co., Ltd. (SHSE:688068) announces an Equity Buyback for CNY 100 million worth of its shares.

New minor risk - Financial data availability

Now 25% overvalued after recent price rise

Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2025 earnings released: CN¥1.27 loss per share (vs CN¥2.47 loss in FY 2024)